

Supplementary Information for High Expression of G9a Induces Cisplatin Resistance in Hepatocellular Carcinoma

Junhao Fu, M.Sc.^{1#}, Min Yu, M.Sc.^{2#}, Wenxia Xu, Ph.D.¹, Shian Yu, M.D.^{2*}

1. Central Laboratory, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, Zhejiang Province, China

2. Department of Hepatobiliary and Pancreatic Surgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, Zhejiang Province, China




Fig.S1: Analysis of the correlation between G9a and hepatocellular carcinoma (HCC) through the public tumor databases. **A.** Analyzing diversity in expression level of G9a (also known as EHMT2) between the normal people and liver cancer patients through the UALCAN tumor database. **B.** Analyzing relationship between G9a expression level and liver cancer staging through the UALCAN tumor database. **C.** Analyzing relationship between G9a expression level and overall survival and **D.** Disease-free survival of liver cancer patients through the GEPIA2 tumor database.

Received: 06/December/2021, Revised: 09/November/2022, Accepted: 09/ November/2022

These authors contributed equally to this work.

*Corresponding Address: Department of Hepatobiliary and Pancreatic Surgery, Affiliated Jinhua Hospital, Zhejiang University School of Medicine, Jinhua, Zhejiang Province, China

Email: ysa513@163.com



Royan Institute
Cell Journal
(Yakhteh)




Fig.S2. Western blot analysis of G9a and H3K9me2 protein levels in HuH7 and SNU387 cells treated with BIX-01294.

A

Some of the targets of Degrasyn				
USP5	USP9x	USP14	USP37	UCH-L1

B

Some of the targets of PR-619													
USP1	USP2	USP4	USP5	USP7	USP8	USP9x	USP10	USP14	USP15	USP16	USP19	USP20	
USP22	USP24	USP28	USP47	USP48	BAP1	YOD1	ATXN3	OTUD5	JOSD2	VCIP135	UCLH3		

C




Fig.S3: Preliminary identification of upstream regulatory factors of G9a in HuH7 cells. **A.** Targets of selective deubiquitinase inhibitor Degrasyn. Yellow indicates targets that overlap with PR-619. **B.** Representative targets of the broad-spectrum deubiquitinase inhibitor PR-619. Yellow indicates targets that overlap with Degrasyn. **C.** Western blot analysis of G9a protein levels in HuH7 cells treated with Degrasyn (0, 5, 10 μ M) and PR-619 (0, 5, 10 μ M) for 24 hours.